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Osteoporosis arises from an imbalance between osteoblastic bone formation and osteoclastic bone
resorption. In this study, we screened molecules frommarine natural products that stimulate osteo-
blast differentiation. We found that phorbaketal A signiﬁcantly stimulates osteoblast differentiation
in mesenchymal cells. Increased interaction of TAZ and Runx2 stimulated phorbaketal A-induced
expression of osteoblastic marker genes. The activation of ERK was important for the stimulation
of differentiation because an inhibitor of ERK blocked phorbaketal A-induced osteogenic differen-
tiation. Taken together, the results showed that phorbaketal A stimulates TAZ-mediated osteoblast
differentiation through the activation of ERK.
Structured summary of protein interactions:
TAZ physically interacts with RUNX2 by pull down (View interaction)
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction differentiation [5,6]. Runx2 is a member of runt, a pair-rule geneOsteoporosis is a common skeletal disease that results in
decreased bone mass and has serious consequences, such as the
promotion of bone fracture and disability. Bone mass in adults is
maintained by the balance between osteoclastic bone resorption
and osteoblastic bone formation. This bone homeostasis is dy-
namic, and the current drug development for osteoporosis has pri-
marily focused on identifying molecules that can regulate the
process by increasing osteoblastic activity or decreasing osteoclas-
tic activity [1,2].
Osteoblast differentiation is a key event in bone formation, and it
is known that cell type-speciﬁc gene regulation plays an important
role in the differentiation process [3,4]. Runx2 is a critical transcrip-
tion factor that regulates the target genes involved in osteoblastchemical Societies. Published by E
h PDZ-binding motif; Runx2,
; ALP, alkaline phosphatase;
nal-regulated kinase; JNK, c-
s and Biotechnology, Korea
2 2 927 9028.of the Drosophila family of transcription factors, and controls the
expression of osteoblast-speciﬁc genes, such as osteocalcin. Dele-
tion of the Runx2 gene inmice leads to a phenotype that completely
lacks ossiﬁcation, suggesting that Runx2 is an essential factor for
osteoblast differentiation [5,6]. Several studies have shown that
Runx2 can interact with many other transcription factors and
co-regulators that enhance or inhibit Runx2 function. Among these
co-regulators, HDAC3, HDAC4, TLE and YAP inhibit the transcrip-
tional activity of Runx2, but Grg5, Rb and TAZ activate Runx2 (for
a review, see [7]).
TAZ (Transcriptional coactivatorwith PDZ-bindingmotif) is a 14-
3-3-binding protein that regulates cell differentiation, proliferation
and development. For its function, TAZ interacts with several tran-
scription factors, including Runx2, PPARc, TEADs, TTF-1/Nkx2.1,
Tbx5, Pax3 and Smad2/3-4 complexes andMyoD [8–16]. The nucle-
ar localization of TAZ and its interaction with these transcription
factors regulates the transcription of their target genes. Certain sig-
naling pathways, including the Hippo and TGFb pathways, regulate
the localization and activity of TAZ. The Hippo signaling pathway
plays an important role in TAZ-mediated cell proliferation and
tumorigenesis [17,18]. TAZ also modulates mesenchymal stem cell
differentiation, with the activation of osteoblast and myoblastlsevier B.V. All rights reserved.
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with Runx2 and stimulates Runx2-mediated gene transcription for
the stimulation of osteoblastic differentiation, but the interaction
with TAZ and PPARc inhibits adipocyte differentiation [8].
Here, we report that phorbaketal A [19] stimulates Runx2-med-
iated gene transcription in osteoblast differentiation. We found
that increased TAZ expression and ERK activity facilitate the osteo-
blast differentiation induced by phorbaketal A.
2. Materials and methods
2.1. Isolation of phorbaketal A
The marine sponge, Phorbas sp. (collected from Gageo Island,
South Korea), was extracted twice with MeOH at room tempera-
ture. This methanolic extract was partitioned between CH2Cl2
and H2O solvents, and the organic layer was then repartitioned be-
tween n-hexane and 15% aqueous MeOH for the removal of lipids.
The MeOH fraction was separated using vacuum column chroma-
tography and eluted with seven different solvent mixtures of
MeOH and water. The fraction from the MeOH/H2O (90/10) solvent
contained a large amount of phorbaketal A (Fig. 1A). For the puri-
ﬁcation of this compound, this fraction was subjected to reversed-
phase preparative HPLC and eluting with AcCN/H2O (65/35).
2.2. Cell culture and osteoblast differentiation
C3H10T1/2 cells weremaintained in Dulbecco’s modiﬁed Eagle’s
medium (DMEM) supplemented with 10% fetal bovine serum (Hy-
clone) and antibiotics (100 units/ml penicillin and 100 lg/ml strep-
tomycin). To induce osteoblast differentiation, the C3H10T1/2 cells
were seeded on 24-well culture plates at a density of 2  104 cells/
cm2; 48 h later, the culture media were changed with DMEM con-
taining 50 lg/ml ascorbic acid, 10 mM b-glycerophosphate and0             1           2.5      5       10
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Fig. 1. Phorbaketal A stimulates osteoblast differentiation. (A) Structure of phorbaketal
increases calcium deposition in a dose-dependent manner. C3H10T1/2 cells were incuba
indicated concentration. After 6 days of differentiation, the cells were stained with Alizar
color. (C) Phorbaketal A (PA) increases alkaline phosphatase activity in a dose-depend
stimulates the expression of osteoblastic marker genes. C3H10T1/2 cells were incubated w
After 6 days of differentiation, the cells were harvested, and total RNA was obtained. Usin
phosphatase (ALP), Dlx5, Runx2, and TAZ were analyzed. Their relative expression was ca
the t-test. (E) C3H10T1/2 cells were treated with phorbaketal A and induced to different
then subjected to immunoblot analysis for Runx2, TAZ, or b-actin.10% FBS (differentiationmedia) for 6 days. The differentiationmed-
ia was replaced every 2 days. Bone marrow-derived humanmesen-
chymal stem cells were purchased from Lonza.
For additional methods, see supplementary materials and
methods.
3. Results
3.1. Phorbaketal A is isolated from the marine sponge Phorbas sp.
In our search for compounds inducing osteoblast differentia-
tion, we screened more than 200 extracts of marine organisms
with calcium deposition activity. Among them, the extracts from
the marine sponge, Phorbas sp., showed signiﬁcantly increased cal-
cium deposition activity, and the activity-guided separation al-
lowed for the isolation of phorbaketal A (Fig. 1A) [19]. Next, to
study its dose-dependent activity in osteoblast differentiation,
C3H10T1/2 cells were incubated with increasing amounts of phor-
baketal A, and the cells were then induced to differentiate into
osteoblasts with differentiation media. The calcium deposition
and alkaline phosphatase activity were then analyzed for the dif-
ferentiation analysis. As shown in Fig. 1B and C, a dose-dependent
induction of calcium deposition and alkaline phosphatase activity
was observed, suggesting that phorbaketal A stimulates osteoblast
differentiation in a dose-dependent manner.
3.2. Phorbaketal A stimulates the marker genes of osteoblast
differentiation
To analyze the activity of phorbaketal A further, osteoblast mar-
ker gene expression was analyzed. C3H10T1/2 cells were incubated
with osteoblast differentiation media in the absence or presence of
phorbaketal A. After 6 days of differentiation, osteoblastic marker
genes, including osteocalcin, Dlx5, and alkaline phosphatase, were  PA (µg/ml)
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ted with osteoblastic differentiation media in the presence of phorbaketal A at the
in Red S solution. Increased calcium deposition activity was indicated by a dark-red
ent manner. Alkaline phosphatase activity in (B) was analyzed. (D) Phorbaketal A
ith osteoblastic differentiation media in the presence of 10 lg/ml of phorbaketal A.
g quantitative real-time PCR (qRT-PCR), the expression of osteocalcin (OC), alkaline
lculated after normalization to the GAPDH level. ⁄indicates a P value; ⁄ for P < 0.01 by
iate for 6 days. Whole cell extracts were harvested and resolved by SDS–PAGE, and
1088 M.R. Byun et al. / FEBS Letters 586 (2012) 1086–1092analyzed by quantitative RT-PCR (qRT-PCR). In these experiments,
an increased expression of these markers was observed (Fig. 1D),
further indicating that this compound has osteogenic potential.
We also observed signiﬁcant expression of Runx2, a key transcrip-
tion factor of osteoblast differentiation, and TAZ protein, a tran-
scriptional co-regulator (Fig. 1E), indicating that the increased
expression of the proteins is important for phorbaketal A-induced
osteogenic differentiation.
3.3. Phorbaketal A stimulates Runx2-mediated gene transcription
Runx2 is a key transcription factor which regulates the pro-
moter of osteoblastic marker genes including osteocalcin. To test
whether phorbaketal A induces Runx2-mediated gene transcrip-
tion, luciferase reporter constructs containing Runx2 binding sites
were transfected into 293T cells with the Runx2 expression plas-
mid, and the reporter activity was analyzed in the presence of
phorbaketal A. As shown in Fig. 2A, Runx2 stimulated reporter
activity, and the activity was further increased by approximately
4-fold in the presence of phorbaketal A, which suggests that phor-
baketal A activates Runx2-mediated gene transcription.
It is known that TAZ physically interacts with Runx2 and acti-
vates Runx2-mediated gene transcription [8]. Next, to test the role
of TAZ in the phorbaketal A induced luciferase reporter activity,
TAZ expression plasmids were introduced into cells with Runx2
expression plasmids and the luciferase reporter plasmids. As
shown in Fig. 2B, TAZ stimulated Runx2-mediated reporter gene
activity, and the activity also increased by approximately 35% in
the presence of phorbaketal A. These results suggest that TAZ
mediates phorbaketal A-induced osteogenic potential through the
activation of Runx2.
Next, to study whether TAZ induces endogenous osteocalcin
gene expression through the Runx2-binding site in the presenceB
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Fig. 2. Phorbaketal A stimulates Runx2-mediated osteoblast differentiation. (A) Stimula
plasmid (0.2 lg/well) was transfected into 293T cells with the 6XOSE2-luc reporter co
osteocalcin promoter. After 24 h of transfection, the cells were incubated with 10 lg/ml
activities. Differences in the transfection efﬁciency were adjusted by normalizing the
calculated and expressed as fold induction. ⁄P < 0.01, t-test. (B) 293T cells were transfec
Runx2 and TAZ expression vectors, and subsequently treated with the indicated concentra
Renilla luciferase activity and expressed as the fold induction compared to the mock con
endogenous osteocalcin promoter in response to phorbaketal A. Stable Flag-tagged TAZ-ex
media in the presence of 10 lg/ml phorbaketal A, and the immunoprecipitates of anti-Fla
control cells. The numbers indicate the relative intensities.of phorbaketal A, chromatin immunoprecipitation analysis was as-
sessed with Flag-tagged TAZ (Flag-TAZ)-overexpressing cells. As
shown in Fig. 2C, Flag-TAZ was recruited into the Runx2-binding
site of the osteocalcin gene promoter, and a 2.4-fold increase in
the recruitment of Flag-TAZ was observed in the presence of phor-
baketal A. The results showed that phorbaketal A stimulates oste-
ocalcin gene expression through the recruitment of TAZ into the
osteocalcin promoter in differentiating cells.
3.4. Phorbaketal A stimulates the physical interaction between TAZ
and Runx2
To understand the mechanism of TAZ-mediated transcriptional
activation in the presence of phorbaketal A, we studied the effects
of phorbaketal A on the physical interaction between TAZ and
Runx2. As shown in Fig. 3A, phorbaketal A signiﬁcantly enhanced
the physical interaction of TAZ with Runx2, indicating that the in-
creased interaction between TAZ and Runx2 stimulates Runx2-
mediated osteogenic gene transcription. Notably, we observed that
ectopically expressed Runx2 was signiﬁcantly stabilized in phor-
baketal A treated cells (Fig. 3A), indicating the positive effect of
phorbketal A in osteogenic differentiation.
In Fig. 2C, increased occupancy of TAZ on the osteocalcin pro-
moter suggested that the localization of TAZ in the nucleus in-
creases in the presence of phorbaketal A. To analyze the cellular
distribution of TAZ after phorbaketal A treatment, immunocyto-
chemical analysis was assessed and TAZ localization was revealed
by green ﬂuorescence signal. In Fig. 3B, increased ﬂuorescence sig-
nal was observed in phorbaketal A treated cells, indicating in-
creased expression of TAZ. We also observed increased nuclear
localization of TAZ in phorbaketal A treated cells. The results sug-
gested that phorbaketal A facilitates nuclear localization of TAZ
somehow. 
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tion of Runx2-driven gene expression by phorbaketal A (PA). The Runx2 expression
nstruct (0.05 lg/well), which contains six copies of the Runx2-binding site in the
of phorbaketal A. After 24 h, cell lysates were prepared for analyzing the luciferase
Fireﬂy luciferase activity to that of Renilla luciferase. The luciferase activity was
ted with a vector encoding a reporter gene containing the 6XOSE2-luc reporter and
tions of phorbaketal A for 24 h. The luciferase activity was normalized to the level of
trol. ⁄P < 0.05, ⁄⁄P < 0.01, t-test. (C) Chromatin immunoprecipitation of TAZ with the
pressing C3H10T1/2 cells (T) were treated for 4 days with osteogenic differentiation
g antibodies were analyzed for osteocalcin promoter occupancy by PCR. Bp indicates
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Fig. 3. Phorbaketal A stimulates Runx2 and TAZ interaction and facilitates the recruitment of TAZ onto the osteocalcin promoter. (A) 293T cells were transfected with HA-
tagged Runx2 and/or Flag-tagged TAZ expression plasmids and incubated with 10 lg/ml phorbaketal A (PA) for 24 h. Whole cell lysates (WCL) were precipitated with Flag-M2
agarose beads. The precipitates and WCL were analyzed by immunoblot analysis with antibodies against HA and TAZ. (B) Phorbaketal A increases nuclear localization of TAZ.
Serum-deprived C3H10T1/2 cells were incubated with 10 lg/ml phorbaketal A. After 24 h, the cells were ﬁxed, and the cellular location of TAZ was analyzed by
immunocytochemistry. A FITC-conjugated secondary antibody was used for the green ﬂuorescence signal. DAPI staining indicates the nuclei of the cells. The arrows in merged
section indicate the cells that show enriched TAZ expression in the nucleus. (C) C3H10T1/2 cells were treated for 2 days with osteogenic differentiation media in the absence
or presence of 10 lg/ml phorbaketal A, cell lysates were prepared, and the phosphorylation status of TAZ at serine 89 was analyzed with a phospho-speciﬁc TAZ antibody.
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for nuclear localization. The phosphorylation of TAZ at serine 89 in-
duces 14-3-3 binding and the cytosolic sequestration of TAZ, and
dephosphorylated TAZ is not subjected to 14-3-3 binding and can
be found in the nucleus [27]. Thus, we studied the phosphorylation
status of TAZ at serine 89 using a phospho-speciﬁc antibody. In the
presence of phorbaketal A, a signiﬁcantly increased level of TAZ
was observed, but the phosphorylation status of TAZ at serine 89
was unchanged (Fig. 3C). Thus, the unphosphorylated form of
TAZ at serine 89 signiﬁcantly increases in the presence of phorbak-
etal A, suggesting that phorbaketal A increases the level of nuclear-
ly localized TAZ and facilitates the physical interaction of TAZ and
Runx2.
3.5. TAZ depletion signiﬁcantly decreases phorbaketal A-mediated
osteogenic stimulation
To study whether TAZ is required in phorbaketal A-mediated
osteoblast differentiation, TAZ knockdown C3H10T1/2 cells were
generated using TAZ-speciﬁc shRNA-producing retroviruses. The
control and TAZ knockdown cells were then incubated with
osteoblast differentiation media in the presence of phorbaketal A
(Fig. 4A). In these experiments, the control cells showed increased
TAZ, Runx2, and Dlx5 gene expression in the presence of phorbak-
etal A; however, the knockdown cells did not show increased
expression even in the presence of phorbaketal A (Fig. 4B),indicating that TAZ plays an important role in phorbaketal A-stim-
ulated osteoblast differentiation.
3.6. Introduction of TAZ in TAZ depleted cells recovers phorbaketal A-
mediated osteogenic marker genes expression
To further study the role of TAZ in phorbaketal A-mediated
osteoblast differentiation, TAZ expression plasmids were intro-
duced into TAZ knockdown C3H10T1/2 cells and recovered TAZ
expression in TAZ depleted cellswas observed in Fig. 5A. Next, phor-
baketal A-mediated osteogenic differentiation activity was ana-
lyzed in control, TAZ-depleted, and TAZ-introduced TAZ-depleted
cells. In Fig. 5B, the TAZ-introduced TAZ-depleted cells showed in-
creased TAZ, Runx2, and Dlx5 gene expression compare to TAZ-
depleted cells or control cells. These results indicate that TAZ is
an important factor in phorbaketal A stimulated osteoblast
differentiation.
3.7. Phorbaketal A stimulates osteoblast differentiation of human
mesenchymal stem cells
To rule out the possibility that the osteogenic potential of phor-
baketal A is not a cell type-speciﬁc response, we studied whether
phorbaketal A stimulates osteoblast differentiation of human
mesenchymal stem cells, which are the origin of osteoblasts in adult
humans. Human mesenchymal stem cells were incubated with
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Fig. 5. Introduction of TAZ in TAZ depleted C3H10T1/2 cells recovers phorbaketal A-mediated osteoblastic marker gene expression. (A) TAZ depleted C3H10T1/2 cells (Ti)
were infected with TAZ expressing retrovirus. After puromycin selection for 7 days, the cell population was ampliﬁed (Ti-TAZ cells). The C3H10T1/2 control (C), TAZ
knockdown (Ti), and TAZ recovered (Ti-TAZ) cells were prepared and the cell lysates were analyzed for the expression of TAZ by immunoblotting. (B) The Cells in (A) were
incubated with osteoblast differentiation media in the absence or presence of 10 lg/ml phorbaketal A (PA). After 6 days of differentiation, total RNA of the above cells was
prepared and the TAZ, Runx2, and Dlx5 expression levels were analyzed by qRT-PCR. The level of GAPDH was analyzed for the control. ⁄P < 0.01, t-test.
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As shown in Fig. 6A and B, phorbaketal A signiﬁcantly activated
the osteogenic differentiation of human mesenchymal stem cells,
as indicated by increased calciumdeposition and osteogenicmarker
gene expression. These results indicated that the effect of phorbak-
etal A is not a cell type-speciﬁc effect, and suggested that phorbak-
etal A might be a potential lead compound for the treatment of
osteoporosis.
3.8. Phorbaketal A stimulates osteoblast differentiation through the
activation of extracellular signal regulated kinase (ERK)
MAPK plays an important role in osteoblast differentiation. To
study the role of phorbaketal A in the signals for osteoblast differ-
entiation, we analyzed the cellular MAPK activity. As shown in
Fig. 7A, the ERK and c-Jun N-terminal kinase (JNK) activities weresigniﬁcantly increased, but p38 MAPK was not stimulated. Next,
to test whether the increased kinase activity is important for the
phorbaketal A-induced osteoblast differentiation, U0126 (an MEK
inhibitor) and SP600125 (a JNK inhibitor) were co-treated with
phorbaketal A. As shown in Fig. 7B, U0126 signiﬁcantly inhibited
calcium deposition, but SP600125 did not show signiﬁcant inhibi-
tion of calcium deposition. Thus, the results showed that ERK, not
JNK, activity induced by phorbaketal A is a critical factor for osteo-
blast differentiation. To further study the effect of U0126
treatment, the expression of osteoblastic marker genes, including
TAZ, Dlx5 and osteocalcin were analyzed, and decreased expres-
sion of them was observed (Fig. 7C). Also, phorbaketal A induced
TAZ expression was also signiﬁcantly inhibited by the treatment
of U0126 (Fig. 7D). Taken together, the results suggest that ERK
activity is important for phorbaketal A-induced osteoblast
differentiation.
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cells were lysed, and the activity of cellular ERK, JNK, and p38 kinases were analyzed by immunoblot analysis. The activation status of the kinases was analyzed using their
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Many research groups are currently attempting to identify
molecules that stimulate osteoblast differentiation for the devel-
opment of drugs for osteoporosis, and natural-product com-
pounds are frequently used for drug screening. In this study, we
screened the natural compounds of marine organisms that stimu-
late osteoblast differentiation. One of the compounds was identi-
ﬁed as phorbaketal A, which displayed a strong osteoblastic
potential based on calcium deposition activity and the expression
of osteoblastic marker genes. In particular, phorbaketal A in-
creases levels of TAZ, a transcriptional regulator, in osteoblast dif-
ferentiation, and TAZ is required for phorbaketal A-mediated
osteoblast differentiation. For its signal transduction, phorbaketal
A stimulates the ERK pathway, and disruption of the signal inhib-
its phorbaketal A-induced osteoblastogenesis. Taken together, the
results show that phorbaketal A is a strong inducer of osteoblast
differentiation.It was shown that MAPK activation could induce Runx2 phos-
phorylation and Runx2-dependent expression of the osteocalcin
gene [20,21]. An examination of the osteocalcin promoter for
MAPK-responsive sequence elements identiﬁed two Runx2-bind-
ing sites [22]. Indeed, an increased skeletal size and calvarial min-
eralization was observed in mice that have constitutively active
MAPK/ERK in their osteoblasts [23]. The FGF2-induced ERK activa-
tion increased the phosphorylation of Runx2 at serine 301 and the
level of the Runx2 protein [24]. Thus, increased ERK activity is a
notable effect of phorbaketal A-mediated osteogenic differentia-
tion. In our result ERK signal increased TAZ expression and the
expression was inhibited by the treatment of ERK inhibitor
(Fig. 7D). We also previously observed that increased TAZ expres-
sion stimulates osteoblast differentiation. Thus, it suggests that in-
creased TAZ expression and interaction with Runx2 is important
for ERK signal-mediated osteogenic stimulation.
JNK is required for the late-stage differentiation of preosteo-
blasts and BMP-2-induced differentiation of preosteoblasts and
1092 M.R. Byun et al. / FEBS Letters 586 (2012) 1086–1092pluripotent cells [25]. The activation of JNK1 increases the cellular
responsiveness to BMP-2 and decreases the binding of inhibitory
Smad6 to the type I BMP receptor [26]. These results suggest that
JNK activity stimulates osteoblast differentiation. We observed that
phorbaketal A stimulates JNK activity; however, JNK activity is not
critical for phorbaketal A-mediated osteoblastic differentiation be-
cause a chemical inhibitor of JNK did not signiﬁcantly inhibit osteo-
blastic differentiation. Presently, we do not know the direct target
molecule of phorbaketal A and speculate that it could be a cellular
receptor or signaling molecule(s) for ERK and JNK activation. Fur-
ther study should address the identiﬁcation of the target molecule.
Our results showed that phorbaketal A regulates cellular
differentiation through TAZ. It has previously been shown that
TAZ interacts with Runx2 [8] and activates its target genes through
the recruitment of transcriptional co-activators [13]. Thus, the in-
creased interaction between TAZ and Runx2 mediated by phorbak-
etal Amay facilitate the recruitment of transcriptional co-activators
to the promoters of osteoblastic genes. Indeed, we observed that
phorbaketal A stimulates localization of TAZ on the promoter of
osteocalcin (Fig. 2C).
TAZ is a 14-3-3 binding protein and is sequestered in the cytosol
after binding with 14-3-3 proteins, and phosphorylation at serine
89 of mouse TAZ is important for 14-3-3 binding and cytosolic
sequesteration of TAZ [27]. Recently it is revealed that Lats kinase,
a component of Hippo signal, phosphorylates the site and induces
proteolytic degradation of TAZ [17]. Thus, the phosphorylation
status of TAZ was analyzed to study the mechanisms by which
phorbaketal A regulates the function of TAZ. Interestingly, we ob-
served that phorbaketal A treatment resulted in a signiﬁcant induc-
tion of unphosphorylated TAZ at serine 89 (Fig. 3C), producing the
unbound form of TAZ in the interaction of 14-3-3. These results sug-
gest that phorbaketal A stimulates induction and nuclear localiza-
tion of TAZ for osteogenic differentiation. At this moment, we do
not know whether phorbaketal A regulates the activity of Lats ki-
nase and effect of the kinase on osteogenic differentiation, but the
study should be assessed for further understanding the effects of
phorbaketal A.
TAZ depletion induced signiﬁcant reduction of osteoblastic
marker genes expression after phorbaketal A treatment, but it
did not produce complete reduction (Fig. 4), indicating that there
are another mechanisms for phorbaketal A induced osteogenic dif-
ferentiation. Indeed, there are other transcriptional co-activators
such as p300 for Runx2-mediated gene transcription and they
may also be involved in phorbaketal A induced osteogenic differen-
tiation. Further study should be addressed for understanding the
mechanism.
Phorbaketal A can stimulate osteoblast differentiation of human
mesenchymal stem cells (Fig. 6), suggesting that phorbaketal A is a
possible candidate for therapeutic reagents for osteoporosis. Thus,
we are currently investigating whether it can induce bone forma-
tion in normal and ovariectomized animal model and developing
several phorbaketal A derivatives with modiﬁed side chains to in-
crease its biological effect.
In summary, we report that phorbaketal A, which was isolated
from the marine sponge, Phorbas sp., stimulated osteoblast differ-
entiation through the induction of TAZ and the activation of ERK,
revealing a novel stimulator for osteoblast differentiation.
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